68Ga-DOTA-FAPI-46 PET/CT Imaging for Restaging in a Patient With Metastatic Pheochromocytoma: Comparison With68Ga-DOTA-TATE PET/CT
Clinical Nuclear Medicine, cilt.49, sa.11, 2024 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 49 Sayı: 11
- Basım Tarihi: 2024
- Doi Numarası: 10.1097/rlu.0000000000005481
- Dergi Adı: Clinical Nuclear Medicine
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Anahtar Kelimeler: Ga-68-DOTA-FAPI-46 PET/CT, pheochromocytoma, Ga-68-DOTA-TATE PET/CT
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Pheochromocytomas (PHEOs) are neural crest-derived tumors originating from the chromaffin cells of the adrenal medulla and were recognized as one of the subtypes of paragangliomas by the World Health Organization in 2022. 68Ga-labeled somatostatin analog (68Ga-DOTA-NOC, 68Ga-DOTA-TOC, and 68Ga-DOTA-TATE) PET imaging has shown significant performance compared with 123MIBG scintigraphy in the diagnosis of paragangliomas. It is now known that fibroblast activation protein (FAP) is overexpressed by various cancer-associated fibroblasts, including PHEOs. We would like to present the findings of 68Ga-DOTA-FAPI-46 PET/CT and 68Ga-DOTA-TATE PET/CT imaging performed for restaging on a 42-year-old man diagnosed with metastatic PHEO.